{"id":"sarcosine-and-ssri","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Serotonin syndrome (rare, with SSRI combination)"}]},"_chembl":{"chemblId":"CHEMBL304383","moleculeType":"Small molecule","molecularWeight":"89.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sarcosine is a glycine transporter-1 inhibitor that increases synaptic glycine levels, potentiating NMDA receptor function through allosteric modulation at the glycine co-agonist site. When combined with an SSRI (selective serotonin reuptake inhibitor), this dual mechanism targets both glutamatergic and serotonergic systems, potentially enhancing efficacy in psychiatric disorders. This combination approach is based on the hypothesis that augmenting SSRI therapy with glutamatergic modulation improves treatment response.","oneSentence":"Sarcosine combined with an SSRI enhances glutamatergic neurotransmission by inhibiting glycine transporter-1 (GlyT1) while simultaneously increasing serotonergic activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:56.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (as adjunctive therapy to SSRI)"},{"name":"Major depressive disorder (treatment-resistant or SSRI-augmentation)"}]},"trialDetails":[{"nctId":"NCT04975100","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-26","conditions":"Major Depressive Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sarcosine and SSRI","genericName":"Sarcosine and SSRI","companyName":"All India Institute of Medical Sciences, Bhubaneswar","companyId":"all-india-institute-of-medical-sciences-bhubaneswar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sarcosine is being studied as an add-on treatment for Major Depressive Disorder, alongside the commonly used SSRI (Selective Serotonin Reuptake Inhibitor). According to ClinicalTrials.gov, Sarcosine is being evaluated for its efficacy and safety in combination with SSRI in patients with Major Depressive Disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}